Pcn214 - Ibritumomab Tiuxetan Radiolabelled With Yttrium Chloride: 4 Years of Use in the 37 Public Hospitals of Paris and in France

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.296
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients With Prior Myeloablative Chemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2005English

Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (With Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

Radioimmunotherapy for B-Cell Lymphoma: Y90 Ibritumomab Tiuxetan and I131 Tositumomab

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

P53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2015English

MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- And 90y-Ibritumomab Tiuxetan

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2009English

A New Pharmacokinetic Model for 90y-Ibritumomab Tiuxetan Based on 3-Dimensional Dosimetry

Scientific Reports
Multidisciplinary
2018English

Positron Emission Tomography/Computed Tomography Before Treatment as a Predictor of 90y-Ibritumomab Tiuxetan Response

Kitakanto Medical Journal
Medicine
2018English

90 Y-Ibritumomab Tiuxetan in Patients With Extra-Nodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (Malt Lymphoma) - The Zeno Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Public and Semi-Public Corporations in France

Law and Contemporary Problems
Law
1961English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy